In this light, zanubrutinib has found application as a compound used to treat B-cell lymphomas characterized by chronic BCR signaling and several studies using zanabrutinib in relapsed/refractory MCL can be found in the literature [44]. The gene discussed is BCR; the disease is B-cell non-Hodgkin lymphoma.